Open-Label Extension Study of GSK1605786A

Stopped early · Phase 3

Conditions studied: Crohn's Disease

In brief

An open-label study to evaluate the safety and effectiveness of GSK1605786A 500 mg twice daily over 108 weeks in adult subjects with Crohn's disease. Subjects completing previous GSK-sponsored studies with GSK1605786A or subjects who withdraw early from Study CCX114157 (maintenance study of GSK1605786A) due to worsening of Crohn's disease requiring a treatment change may be eligible to participate. The primary objective is to evaluate the safety of GSK1605786A, as assessed by recording of adverse events, clinical laboratory parameters, vital signs and electrocardiogram. Secondary objectives will include assessments of effectiveness of long-term treatment with GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), SF-36v2, EQ-5D, Work and Productivity Activity Impairment-Crohn's Disease (WPAI-CD) and receipt of disability.

Key facts

Study ID

NCT01318993

Run by

GlaxoSmithKline

People needed

399

Starts

2011-04-01

Expected to finish

2013-10-29

Last updated by the study team

2017-09-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previous participation in a GSK-sponsored study with GSK1605786A
• Written informed consent prior to any study-specific procedures
• Female subjects: To be eligible, females of child-bearing potential must be sexually inactive or commit to consistent and correct use of a contraceptive method of birth control with less than 1% failure rate

You may not qualify if…

• If female, is pregnant, has a positive pregnancy test or is breast-feeding, or is planning to become pregnant
• Subjects with known or suspected coeliac disease or a positive screening test for anti-tissue transglutaminase antibodies should have been excluded from enrolment into any induction study. Subjects in whom a diagnosis of coeliac disease is subsequently suspected should be tested for anti-tissue transglutaminase antibodies and excluded or withdrawn from the study upon positive test result
• Fixed symptomatic stenoses or strictures of small bowel or colon
• Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the study period
• Current sepsis or infections requiring intravenous antibiotic therapy greater than 2 weeks
• Evidence of hepatic dysfunction or viral hepatitis
• Subjects who have demonstrated safety or tolerability issues during participation in a previous study with GSK1605786A which, in the opinion of the investigator, was possibly related to study treatment and poses an unacceptable risk to the subject.

Where it is running

• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Anaheim, California, United States
• GSK Investigational Site — La Jolla, California, United States
• GSK Investigational Site — San Diego, California, United States
• GSK Investigational Site — San Francisco, California, United States
• GSK Investigational Site — Aurora, Colorado, United States
• GSK Investigational Site — Lakewood, Colorado, United States
• GSK Investigational Site — Littleton, Colorado, United States
• GSK Investigational Site — Hamden, Connecticut, United States
• GSK Investigational Site — New Haven, Connecticut, United States
• GSK Investigational Site — Washington D.C., District of Columbia, United States
• GSK Investigational Site — Jacksonville, Florida, United States
• GSK Investigational Site — Port Orange, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Suwanee, Georgia, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Indianapolis, Indiana, United States
• GSK Investigational Site — Lexington, Kentucky, United States
• GSK Investigational Site — Hammond, Louisiana, United States
• GSK Investigational Site — Monroe, Louisiana, United States
• GSK Investigational Site — Chevy Chase, Maryland, United States
• GSK Investigational Site — Towson, Maryland, United States
• GSK Investigational Site — Towson, Maryland, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Little Rock, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.